1
|
Mankan AK, Shankar A, Limaye S, Ajaikumar BS, Nachane P, Singh N, Dawkhar S, Batra U, Bhosekar A, Ganguly S, Gawli P, Debnath K, Padalalu V, Reddy P, Sundaramoorthy S, Naveen KK, Bondarde S, Kumar P, Davis S, Ramkissoon SH, Chacko RT, Vidal L, Chico I, Hegedus A, Gupta S, Saini KS. Cancer Trials Ecosystem in India-Ready for Prime Time? JCO Glob Oncol 2024; 10:e2300405. [PMID: 38870438 DOI: 10.1200/go.23.00405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 04/12/2024] [Indexed: 06/15/2024] Open
Abstract
Executing global clinical trials for cancer is a long, expensive, and complex undertaking. While selecting countries global studies, sponsors must consider several aspects including patient pool, quality of trained investigators, competing trials, availability of infrastructure, and financial investment versus returns. With a large, often treatment-naïve, and diverse patient pool, relatively low cost, good quality health care facilities in urban areas, and a robust and well-trained workforce, India offers several advantages for conducting oncology clinical trials. However, there remains challenges, including a shifting regulatory environment in recent decades. With the implementation of the New Drugs and Clinical Trial Rules in 2019, India's regulatory atmosphere seems to have stabilized. In this article, we present a review of the evolving clinical trial landscape in India, highlight the current regulatory scenario, and discuss the advantages and challenges of selecting India as a potential location for conducting global oncology clinical trials.
Collapse
Affiliation(s)
| | - Abhishek Shankar
- Department of Radiation Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Delhi, India
| | | | | | | | - Navneet Singh
- PostGraduate Institute of Medical Education and Research, Chandigarh, India
| | | | - Ullas Batra
- Rajiv Gandhi Cancer Centre, New Delhi, India
| | | | | | | | | | | | | | | | | | | | | | - Sanish Davis
- Indian Society for Clinical Research, Mumbai, India
| | | | | | | | | | | | - Sudeep Gupta
- Tata Memorial Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Kamal S Saini
- Fortrea Inc, Durham, NC
- Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| |
Collapse
|
2
|
Swain CK, Padhee S, Sahoo U, Rout HS, Swain PK. Changing patterns of cancer burden among elderly across Indian states: Evidence from the global burden of disease study 1990-2019. Aging Med (Milton) 2023; 6:254-263. [PMID: 37711257 PMCID: PMC10498831 DOI: 10.1002/agm2.12264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 07/27/2023] [Accepted: 08/06/2023] [Indexed: 09/16/2023] Open
Abstract
Objective To investigate the trends and patterns of the cancer burden among the elderly in different regions of India at a subnational level. Methods Data were extracted from the Global Burden of Disease (GBD) Studies India Compare 2019. Prevalence rate, disability-adjusted life years (DALY), and annual percentage change techniques were used to analyze data. Results The three age groups with the highest prevalence of cancer were those aged 60-64 years, 65-69 years, and 70-74 years. In 2019, The prevalence of cancer among the elderly ranged from 7048.815 in Karnataka to 5743.040 in Jharkhand. Kerala has the most significant annual percentage change in the cancer prevalence rate of 0.291 between 1990 and 2019. The highest DALY rate was observed among individuals aged 80-84 years in 2019. That year, the DALY rate among the elderly was 8112.283 in India. The top five cancers with higher DALY rates among the elderly in India in 2019 were tracheal, bronchus, and lung cancer (908.473), colon and rectum cancer (752.961), stomach cancer (707.464), breast cancer (597.881), and lip and oral cavity cancer (557.637). Conclusion Elderly individuals demonstrated a higher vulnerable to cancer compared to other age groups. There is a need for state-specific government intervention to minimize the risk of cancer among the elderly due to the heterogeneity in the burden of cancer across Indian states.
Collapse
Affiliation(s)
- Chandan Kumar Swain
- Department of Analytical & Applied EconomicsUtkal UniversityBhubaneswarOdishaIndia
| | - Sourav Padhee
- Department of StatisticsUtkal UniversityBhubaneswarOdishaIndia
| | - Umakanta Sahoo
- Department of StatisticsSambalpur UniversitySambalpurOdishaIndia
| | - Himanshu Sekhar Rout
- Department of Analytical & Applied EconomicsUtkal UniversityBhubaneswarOdishaIndia
- RUSA Centre of Excellence in Public Policy and GovernanceUtkal UniversityBhubaneswarOdishaIndia
| | | |
Collapse
|
3
|
Abdul-Sater Z, Mukherji D, Adib SM, Shamseddine A, Abu-Sitta G, Fadhil I, Sullivan R, Omari AA, Saleh S, Taher A. Cancer registration in the Middle East, North Africa, and Turkey (MENAT) region: A tale of conflict, challenges, and opportunities. Front Oncol 2022; 12:1050168. [PMID: 36505790 PMCID: PMC9730320 DOI: 10.3389/fonc.2022.1050168] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Accepted: 11/07/2022] [Indexed: 11/27/2022] Open
Abstract
Cancer registration is a core component of national and regional cancer control strategies. In the Middle East, North-Africa and Turkey (MENAT) region, capacity and resources for cancer registration is variable and shaped by multiple contextual challenges. This viewpoint maps out practical recommendations around cancer registration, in an attempt to inform cancer control planning, policy, and implementation. The recommendations laid out in this viewpoint are informed by the discussions held at the Initiative for Cancer Registration in the MENAT (ICRIM) virtual workshop, which convened registry managers, policy makers, and international agencies from 19 countries in the MENAT region. The discussions were distilled in four categories of recommendations, revolving around cancer registration procedures, collaborative governance, putting cancer registration on the map, and capacity building. This viewpoint provides a much-needed mapping of practical recommendations around cancer registration, informed by direct key stakeholders in the region. These practical recommendations offer a road map for policy making, cancer control planning, and future regional capacity strengthening initiatives.
Collapse
Affiliation(s)
- Zahi Abdul-Sater
- Global Health Institute, American University of Beirut, Beirut, Lebanon
| | - Deborah Mukherji
- Department of Hematology/Oncology, American University of Beirut Medical Center, American University of Beirut, Beirut, Lebanon
| | - Salim M. Adib
- Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
| | - Ali Shamseddine
- Department of Hematology/Oncology, American University of Beirut Medical Center, American University of Beirut, Beirut, Lebanon
| | - Ghassan Abu-Sitta
- Global Health Institute, American University of Beirut, Beirut, Lebanon
| | | | - Richard Sullivan
- Institute of Cancer Policy & Conflict & Health Research Group, King’s College London, London, United Kingdom
| | - Amal Al Omari
- King Hussein Cancer Center, Office of Scientific Affairs and Research (OSAR), Amman, Jordan
| | - Shadi Saleh
- Global Health Institute, American University of Beirut, Beirut, Lebanon
| | - Ali Taher
- Department of Hematology/Oncology, American University of Beirut Medical Center, American University of Beirut, Beirut, Lebanon,*Correspondence: Ali Taher,
| |
Collapse
|
4
|
Mehrotra R, Yadav K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol 2022; 13:209-218. [PMID: 35433294 PMCID: PMC8966510 DOI: 10.5306/wjco.v13.i3.209] [Citation(s) in RCA: 37] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 06/17/2021] [Accepted: 03/07/2022] [Indexed: 02/06/2023] Open
Abstract
Breast cancer is the commonest malignancy among women globally. From being fourth in the list of most common cancers in India during the 1990s, it has now become the first. In this review, we examine the available literature to understand the factors that contributed to the high burden of breast cancer in the country. We also provide the landscape of changes in the field of early diagnosis and the treatment modalities as well as the limitations of the Indian healthcare delivery systems (e.g., delayed diagnosis, human resources and funding for treatment). This review also sheds light on the newer interventions and the future of breast cancer management keeping in mind the coronavirus disease 2019 imposed limitations.
Collapse
Affiliation(s)
- Ravi Mehrotra
- Department of Health Research, Ministry of Health and Family Welfare, India Cancer Research Consortium, New Delhi 110001, India
- CHIP Foundation, Noida 201301, India
| | - Kavita Yadav
- Centre of Social Medicine & Community Health, Jawahar Lal Nehru University, New Delhi 110067, India
| |
Collapse
|
5
|
Busheri L, Dixit S, Nare S, Alhat R, Thomas G, Jagtap M, Navgire R, Shinde P, Banale R, Unde R, Reddy R, Shaikh S, Konnur A, Namewar N, Bapat A, Patil A, Johari R, Kushwaha R, Kumari W, Varghese B, Deshpande P, Deshmukh C, Kelkar DA, Shashidhara LS, Koppiker CB, Kulkarni M. Breast cancer biobank from a single institutional cohort in an urban setting in india: Tumor characteristics and survival outcomes. Cancer Treat Res Commun 2021; 28:100409. [PMID: 34098400 DOI: 10.1016/j.ctarc.2021.100409] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/20/2021] [Accepted: 05/25/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND A breast cancer biobank with retrospectively collected patient data and FFPE tissue samples was established in 2018 at Prashanti Cancer Care Mission, Pune, India. It runs a cancer care clinic with support from a single surgeon's breast cancer practice. The clinical data and tissue sample collection is undertaken with appropriate patient consent following ethical approval and guidelines. METHODS The biobank holds clinical history, diagnostic reports, treatment and follow-up information along with FFPE tumor tissue specimens, adjacent normal and, in few cases, contralateral normal breast tissue. Detailed family history and germline mutational profiles of eligible and consenting patients and their relatives are also deposited in the biobank. RESULTS Here, we report the first audit of the biobank. A total number of 994 patients with breast disease have deposited consented clinical records in the biobank. The majority of the records (80%, n = 799) are of patients with infiltrating ductal carcinoma (IDC). Of 799 IDC patients, 434 (55%) have deposited tumor tissue in the biobank with consent. In addition, germline mutation profiles of 84 patients and their family members are deposited. Follow-up information is available for 85% of the 434 IDC patients with an average follow-up of 3 years. CONCLUSION The biobank has aided the initiation of translational research at our center in collaboration with eminent institutes like IISER Pune and SJRI Bangalore to evaluate profiles of breast cancer in an Indian cohort. The biobank will be a valuable resource to the breast cancer research community, especially to understand South Asian profiles of breast cancer.
Collapse
Affiliation(s)
| | - Santosh Dixit
- Prashanti Cancer Care Mission, Pune; Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Ankita Patil
- Prashanti Cancer Care Mission, Pune; Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune
| | | | - Roli Kushwaha
- Prashanti Cancer Care Mission, Pune; Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune
| | | | | | | | | | - Devaki A Kelkar
- Prashanti Cancer Care Mission, Pune; Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune
| | - L S Shashidhara
- Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune; Ashoka University, Sonipat, Delhi
| | - Chaitanyanand B Koppiker
- Prashanti Cancer Care Mission, Pune; Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune
| | - Madhura Kulkarni
- Prashanti Cancer Care Mission, Pune; Center for Translational Cancer Research, a Joint venture between Prashanti Cancer Care Mission and IISER Pune.
| |
Collapse
|
6
|
Satagopan JM, Stroup A, Kinney AY, Dharamdasani T, Ganesan S, Bandera EV. Breast cancer among Asian Indian and Pakistani Americans: A surveillance, epidemiology and end results-based study. Int J Cancer 2020; 148:1598-1607. [PMID: 33099777 DOI: 10.1002/ijc.33331] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 09/28/2020] [Accepted: 09/30/2020] [Indexed: 11/12/2022]
Abstract
Breast cancer incidence is increasing among Asian Indian and Pakistani women living in the United States. We examined the characteristics of breast cancer in Asian Indian and Pakistani American (AIPA) and non-Hispanic white (NHW) women using data from the surveillance, epidemiology and end results (SEER) program. Breast cancer incidence rates were estimated via segmented Poisson regression using data between 1990 and 2014 from SEER 9 registries, including New Jersey and California. Disease characteristics, treatment and survival information between 2000 and 2016 for 4900 AIPA and 482 250 NHW cases diagnosed after age 18 were obtained from SEER 18 registries and compared using descriptive analyses and multivariable competing risk proportional hazards regression. Breast cancer incidence was lower in AIPA than NHW women, increased with age and the rate of increase declined after age of 46 years. AIPA women were diagnosed at significantly younger age (mean (SD) = 54.5 (13.3) years) than NHW women (mean (SD) = 62 (14) years, P < .0001) and were more likely than NHW cases (P < .0001) to have regional or distant stage, higher grade, estrogen receptor-negative, progesterone receptor-negative, triple-negative or human epidermal growth factor receptor 2-enriched tumors, subcutaneous or total mastectomy, and lower cumulative incidence of death due to breast cancer (hazard ratio = 0.79, 95% CI: 0.72-0.86, P < .0001). AIPA had shorter median follow-up (52 months) than NHW cases (77 months). Breast cancer in AIPA women has unique characteristics that need to be further studied along with a comprehensive evaluation of their follow-up patterns.
Collapse
Affiliation(s)
- Jaya M Satagopan
- Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA.,Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| | - Antoinette Stroup
- Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA.,Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.,New Jersey State Cancer Registry, State of New Jersey Department of Health, New Brunswick, New Jersey, USA
| | - Anita Y Kinney
- Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA.,Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| | - Tina Dharamdasani
- Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA
| | - Shridar Ganesan
- Clinical Investigations and Precision Therapeutics Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| | - Elisa V Bandera
- Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey, USA.,Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| |
Collapse
|
7
|
Kapoor R, Shome D, Vadera S, Kumar V, Ram MS. QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study. PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN 2020; 8:e2843. [PMID: 32983753 PMCID: PMC7489598 DOI: 10.1097/gox.0000000000002843] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 03/20/2020] [Indexed: 02/06/2023]
Abstract
Current treatment modalities are limited in their approach and success for hair loss. QR 678 & QR 678 Neo are new formulations, consisting of a combination of growth factors and peptides. This study demonstrates safety analysis of QR 678 & QR 678 Neo formulation, using in vitro cytotoxicity assay and in vivo animal efficacy. METHODS Factors including vascular endothelial growth factor, basic fibroblast growth factor, insulin-like growth factor-1, keratinocyte growth factor, and copper tripeptide 1 (QR 678) or their biomimetic peptides (QR678 Neo) were suspended in a sterile injectable vehicle. The 3-2,5-diphenyl tetrazolium bromide assay was used to explore the cytotoxic effects of each factor used in the compositions in human keratinocyte cell and human fibroblast cell assays. An in vivo analysis, wherein study animals were given intradermal QR 678 & QR 678 Neo injections, was conducted to assess whether the formulations produce hair growth. Also, hair follicle viability was checked by intradermal injection of the pharmaceutical compositions in secondary alopecia. RESULTS In both formulations, a positive response was observed with respect to the number of mice exhibiting hair growth at the injection sites. The injections caused retention of hair in a 0.25-cm radius around the injection site. On cytotoxicity study, all the factors were found to be safe in human keratinocyte cell and human fibroblast cell assay. A positive response was demonstrated in animals on treatment with the chemotherapeutic agent. CONCLUSIONS Intradermal injections of QR 678 & QR 678 Neo hair growth factor formulations are a safe and efficacious option for alopecia. Results seem encouraging enough to warrant a trial in humans with secondary alopecia, post cancer chemotherapy.
Collapse
Affiliation(s)
- Rinky Kapoor
- From the Department of Dermatology, Cosmetic Dermatology and Dermato-Surgery, The Esthetic Clinics, Mumbai, India
| | - Debraj Shome
- Department of Facial Plastic Surgery & Facial Cosmetic Surgery, The Esthetic Clinics, Mumbai, India
| | - Sapna Vadera
- Department of Facial Plastic Surgery & Facial Cosmetic Surgery, The Esthetic Clinics, Mumbai, India
| | - Vaibhav Kumar
- Department of Facial Plastic Surgery & Facial Cosmetic Surgery, The Esthetic Clinics, Mumbai, India
- Department of Clinical Research, The Esthetic Clinics, Mumbai, India
| | - Male Shiva Ram
- The Department of Research and Biostatistics, The Esthetic Clinics, Mumbai, India
| |
Collapse
|
8
|
Li H, Zhou Y, Cheng H, Tian J, Yang S. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells. Exp Mol Pathol 2020; 115:104481. [PMID: 32497621 DOI: 10.1016/j.yexmp.2020.104481] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Revised: 04/28/2020] [Accepted: 05/30/2020] [Indexed: 12/17/2022]
Abstract
Competing endogenous RNA (ceRNA) networks consisted of long non-coding RNA (lncRNA), microRNA (miRNA) and mRNAs have aroused great interests recently. The current study aims to probe the mechanisms of lncRNA TMPO-AS1 in ovarian cancer (OC) development. A 5-fluorouracil (5-FU)-resistant subline of OC SKOV3 cells was developed, and differentially expressed lncRNAs in OC tissues and SKOV3 cells were analyzed. The miRNAs, genes and signaling pathways interacted with TMPO-AS1 were predicted and validated. TMPO-AS1 and the validated miRNA were inhibited to analyze their roles in malignant behaviors and 5-FU resistance of OC cells. In vivo studies were performed by inducing xenograft tumors in nude mice. Consequently, TMPO-AS1 was highly expressed in OC tissues and SKOV3 cells. TMPO-AS1 regulated transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) through sponging miR-200c in OC cells, during which the PI3K/Akt signaling pathway was activated. Silenced TMPO-AS1 and over-expressed miR-200c inhibited epithelial-mesenchymal transition (EMT), invasion, migration and 5-FU resistance of OC cells. This study demonstrated that silencing of TMPO-AS1 might attenuate OC progression through inhibiting the invasion, metastasis and drug resistance of OC cells via the miR-200c/TMEFF2 network and the disruption of the PI3K/Akt signaling pathway.
Collapse
Affiliation(s)
- Haoshan Li
- Department of Obstetrics and Gynecology, Huaihe Hospital of Henan University, Kaifeng 475001, Henan, PR China
| | - Yan Zhou
- Department of Obstetrics and Gynecology, Huaihe Hospital of Henan University, Kaifeng 475001, Henan, PR China
| | - Hailing Cheng
- Department of Obstetrics and Gynecology, Huaihe Hospital of Henan University, Kaifeng 475001, Henan, PR China
| | - Jun Tian
- Department of Obstetrics and Gynecology, Huaihe Hospital of Henan University, Kaifeng 475001, Henan, PR China.
| | - Shaoqin Yang
- Department of Obstetrics and Gynecology, Huaihe Hospital of Henan University, Kaifeng 475001, Henan, PR China
| |
Collapse
|
9
|
Agoramoorthy G. Can Yoga Practice Minimize Cancer Risks to Indian Women? Int J Yoga 2019; 12:177-178. [PMID: 31543626 PMCID: PMC6746056 DOI: 10.4103/ijoy.ijoy_14_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
10
|
Singh M, Prasad CP, Singh TD, Kumar L. Cancer research in India: Challenges & opportunities. Indian J Med Res 2019; 148:362-365. [PMID: 30665997 PMCID: PMC6362726 DOI: 10.4103/ijmr.ijmr_1711_18] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Affiliation(s)
- Mayank Singh
- Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110 029, India
| | - Chandra Prakash Prasad
- Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110 029, India
| | - Thoudam Debraj Singh
- Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110 029, India
| | - Lalit Kumar
- Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110 029, India
| |
Collapse
|
11
|
Giri K, Mehta A, Ambatipudi K. In search of the altering salivary proteome in metastatic breast and ovarian cancers. FASEB Bioadv 2019; 1:191-207. [PMID: 32123828 PMCID: PMC6996400 DOI: 10.1096/fba.2018-00029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2018] [Revised: 10/31/2018] [Accepted: 11/16/2018] [Indexed: 12/16/2022] Open
Abstract
Breast and ovarian cancers, the most common cancers in women in India, are expected to rise in the next decade. Metastatic organotropism is a nonrandom, predetermined process which represents a more lethal and advanced form of cancer with increased mortality rate. In an attempt to study organotropism, salivary proteins were analyzed by mass spectrometry indicative of pathophysiology of breast and ovarian cancers and were compared to healthy and ovarian chemotherapy subjects. Collectively, 646 proteins were identified, of which 409 proteins were confidently identified across all four groups. Network analysis of upregulated proteins such as coronin-1A, hepatoma-derived growth factor, vasodilator-stimulated phosphoprotein (VASP), and cofilin in breast cancer and proteins like coronin-1A, destrin, and HSP90α in ovarian cancer were functionally linked and were known to regulate cell proliferation and migration. Additionally, proteins namely VASP, coronin-1A, stathmin, and suprabasin were confidently identified in ovarian chemotherapy subjects, possibly in response to combined paclitaxel and carboplatin drug therapy to ovarian cancer. Selected representative differentially expressed proteins (eg, gelsolin, VASP) were validated by western blot analysis. Results of this study provide a foundation for future research to better understand the organotropic behavior of breast and ovarian cancers, as well as neoadjuvant drug response in ovarian cancer.
Collapse
Affiliation(s)
- Kuldeep Giri
- Department of BiotechnologyIndian Institute of Technology RoorkeeRoorkeeIndia
| | - Anurag Mehta
- Rajiv Gandhi Cancer Institute and Research CentreDelhiIndia
| | - Kiran Ambatipudi
- Department of BiotechnologyIndian Institute of Technology RoorkeeRoorkeeIndia
| |
Collapse
|
12
|
Sharma-Oates A, Shaaban AM, Tomlinson I, Wynne L, Cazier JB, Sundar S. Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India. PRECISION CLINICAL MEDICINE 2018; 1:75-87. [PMID: 35693198 PMCID: PMC8985795 DOI: 10.1093/pcmedi/pby010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2018] [Revised: 07/17/2018] [Accepted: 07/23/2018] [Indexed: 12/15/2022] Open
Abstract
Breast and ovarian cancers now account for one in three cancers in Indian women and their incidence is rising. Major differences in the clinical presentation of breast and ovarian cancers exist between India and the United Kingdom. For example, Indian patients with breast cancer typically present a decade earlier than in the UK. Reasons for this could be multifactorial, including differences in underlying biology, environmental risks, and other systematic factors including access to screening. One possible explanation lies in variable incidence or penetrance of germline mutations in genes such as BRCA1 and BRCA2. We performed a methodical database and literature review to investigate the prevalence and spectrum of high-risk cancer susceptibility genes in Indian patients with breast and ovarian cancers. We identified 148 articles, but most studies were small, with inconsistent inclusion criteria and based on heterogeneous technologies, so that mutation frequency could not be reliably ascertained. Data were also often lacking on penetrance, histopathology, and survival outcomes. After filtering out unsuitable studies, only 13 remained, comprising 1028 patients. Large-scale research studies are urgently needed to determine mutation prevalence, spectra, and clinico-pathological features, and hence derive guidelines for screening, treatment, and prevention specific to the Indian population.
Collapse
Affiliation(s)
- Archana Sharma-Oates
- Centre for Computational Biology, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
| | - Abeer M Shaaban
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
- Department of Cellular Pathology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham, UK
| | - Ian Tomlinson
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
| | - Luke Wynne
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
| | - Jean-Baptiste Cazier
- Centre for Computational Biology, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
| | - Sudha Sundar
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, Haworth Building, University of Birmingham, Edgbaston, Birmingham, UK
- Pan-Birmingham Gynaecological Cancer Centre, City Hospital, Dudley Road, Birmingham, West Midlands, UK
| |
Collapse
|
13
|
He W, Zhang P, Ye M, Chen Z, Wang Y, Chen J, Yao F. Polymorphisms of the Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene are Associated with Ovarian Cancer, and with the Prognostic Factors of Grade and Stage, in Women in Southern China. Med Sci Monit 2018; 24:2360-2367. [PMID: 29670073 PMCID: PMC5928851 DOI: 10.12659/msm.910058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND The aim of this study was to determine whether polymorphisms of the Ras-association domain family 1 isoform A (RASSF1A) gene were associated with ovarian cancer and with tumor grade and stage, which affect the prognosis of ovarian cancer, in women in Southern China. MATERIAL AND METHODS Women from Southern China with histologically confirmed, graded and staged ovarian cancer (n=1,375), and cancer-free controls (n=1,227), provided samples of peripheral blood. DNA was extracted from the blood samples, and five tagging single nucleotide polymorphisms (SNPs) (rs4688728G>T, rs72932987C>T, rs1989839C>T, rs2073497A>C, and rs2236947A>C) were evaluated using an online assay-by-design platform. Polymerase chain reaction (PCR) DNA amplification was performed and computational haplotyping analysis of genetic associations between the five tagging SNPs was performed to identify frequent haplotypes in women with ovarian cancer, and the associations with tumor grade and stage. RESULTS In women in Southern China, the CT genotype of rs1989839 was associated with the patients with ovarian cancer (P=0.001), and was significantly correlated with tumor grade and stage (P=0.008). One of the remaining four SNPs studied, rs2073497A>C showed an association with the prognostic factors of grade and stage, but this association did not reach statistical significance. CONCLUSIONS Polymorphisms of the RASSF1A gene, most significantly the CT genotype of rs1989839, might play a role in the development and prognosis of ovarian cancer in women in Southern China. To our knowledge, this is the first study to demonstrate an association between polymorphisms in the RASSF1A gene in ovarian cancer.
Collapse
Affiliation(s)
- Wei He
- Department of Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland)
| | - Pengyuan Zhang
- Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland)
| | - Min Ye
- The Reproductive Medical Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland)
| | - Zhikang Chen
- School of Public Health, Fudan University, Shanghai, China (mainland)
| | - Yizi Wang
- The Reproductive Medical Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland)
| | - Jie Chen
- Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland)
| | - Fengjuan Yao
- Department of Ultrasound, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (mainland)
| |
Collapse
|
14
|
Mehrotra R, Kaushik R. A stitch in time saves nine: Answer to the cancer burden in India. Indian J Med Res 2018; 147:121-124. [PMID: 29806598 PMCID: PMC5991128 DOI: 10.4103/ijmr.ijmr_388_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Indexed: 11/23/2022] Open
Affiliation(s)
- Ravi Mehrotra
- ICMR-National Institute of Cancer Prevention & Research, Noida 201 301, Uttar Pradesh, India
| | - Ravi Kaushik
- Division of Preventive Oncology, ICMR-National Institute of Cancer Prevention & Research, Noida 201 301, Uttar Pradesh, India
- ICMR-National Institute of Cancer Prevention & Research, Noida 201 301, Uttar Pradesh, India
| |
Collapse
|